Nasdaq

Alexion Receives FDA Approval for New Advanced Formulation of ULTOMIRIS® (ravulizumab-cwvz) with Significantly Reduced Infusion Time

– ULTOMIRIS is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) – PNH is a blood disorder characterized by complement-mediated ...
Nasdaq

Alexion Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19

– Company will conduct further analysis of trial data to determine next steps – – No new safety findings were observed for ULTOMIRIS use in COVID-19 – BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals ...
FiercePharma

Alexion snares OK for quicker-infusing Ultomiris formula—and a subQ version is on the horizon

Alexion Pharmaceuticals has wasted no time converting patients to its next-generation rare disease med Ultomiris. Now, it's looking to make the switch to its Soliris successor a little easier, thanks ...
Healio

FDA approves Ultomiris for children with paroxysmal nocturnal hemoglobinuria

Please provide your email address to receive an email when new articles are posted on . The FDA approved ravulizumab-cwvz injection to treat children aged 1 month and older with paroxysmal nocturnal ...